Interim report
Page 1
Q3 Q3 ∆ Jan-Sep Jan-Sep ∆ Oct 2025- Full year SEKm 2026 2025 % 2026 2025 % Sep 2026 2025 Net sales 2,599 2,429 7 7,965 7,709 3 10,698 10,442 EBITA 330 270 22 1,004 920 9 1,501 1,417 EBITA margin, % 12.7 11.1 12.6 11.9 14.0 13.6 Adjusted EBITA 298 270 11 972 920 6 1,311 1,259 Adjusted EBITA margin, % 11.5 11.1 12.2 11.9 12.3 12.1 Profit/loss before taxes 179 111 61 551 429 28 894 772 Profit for the period 128 82 56 386 302 28 646 562 Earnings per share (EPS), before/after dilution, SEK 1.05 0.66 59 3.15 2.47 28 5.28 4.59 Cash flow from operating activities 236 145 62 505 504 0 1,393 1,392 The positive development across AddLife’s companies continues, with stronger margins, solid growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, something we have been preparing for a long time. Fredrik Dalborg, President and CEO THIRD QUARTER Net sales increased by 7 percent to SEK 2,599 million (2,429). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent and acquired growth amounted to 3 percent. Adjusted EBITA increased by 11 percent to 298 (270), corresponding to an adjusted EBITA margin of 11.5 percent (11.1). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million. EBITA amounted to SEK 330 million (270). Profit after tax increased by 56 percent to SEK 128 million (82). Earnings per share amounted to SEK 1.05 (0.66). Cash flow from operating activities increased by 62 percent to SEK 236 million (145). During the quarter, the acquisition of Unicam Sistemas Analíticos Lda, Portugal, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 110 million. After the end of the interim period, the acquisition of Lehnen GmbH, Germany, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 55 million. JANUARY – SEPTEMBER, 2026 Net sales increased by 3 percent to SEK 7,965 million (7,709). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent, acquired growth amounted to 2 percent. Adjusted EBITA increased by 6 percent to 972 (920), corresponding to an adjusted EBITA margin of 12.2 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million. EBITA amounted to SEK 1,004 million (920). Profit after tax increased by 28 percent to SEK 386 million (302). Earnings per share amounted to SEK 3.15 (2.47). For the latest 12 ‑ month period, earnings per share amounted to 5.28 (3.23). Cash flow from operating activities amounted to SEK 505 million (504). The equity ratio was 44 percent (43). Return on working capital (P/WC) amounted to 63 percent (62). Three acquisitions were completed during and one acquisition after the interim period. The acquisitions are expected to contribute annual net sales of approximately SEK 350 million. 4 % ORGANIC GROWTH 11 % EBITA GROWTH 11.5% EBITA MARGIN 63% P/WC INTERIM REPORT JANUARY 1 - SEPTEMBER 30, 2026 The positive development in the companies continues, and the pace of acquisitions is increasing AddLife | Interim report Q3 2026 1
Page 2
COMMENTS BY THE CEO The positive development in the companies continues, and the pace of acquisitions is increasing “The posi ve development across AddLife’s companies con nues, with stronger margins, solid growth and improved cash flow. The opera onal improvements and strengthened balance sheet have enabled increased acquisi on ac vity, something we have been preparing for a long me.” Fredrik Dalborg, President and CEO Good sales growth AddLife’s sales increased by 7 percent during the quarter, with positive development in both Labtech and Medtech. The increased pace of acquisitions made a clear contribution to growth. The customer activity is normally lower during the summer month, particularly within elective surgery and research, and deliveries of larger instruments and capital goods are also often lower. In Spain, healthcare labor disputes continued to hold back demand during the quarter. Despite this, growth was healthy, driven by dedicated and structured sales efforts as well as the continuous introduction of new, advanced products. Sales development in the Nordic region was stable, while growth increased in the UK and Ireland. In Eastern Europe, growth was strong, driven by sound underlying economic development and increased investments in healthcare and research. In September, customer activity increased again, leading to higher demand and stronger order intake. Margins continue to improve Strengthening margins and increasing profit is our highest financial priority. Margins strengthened during the quarter and total profit growth was good. We can clearly see that the introduction of new advanced products contributes to improved gross margins. These products sometimes also require investments in qualified resources, but this is offset by the higher gross margins. Offering new technologies and advanced products is a clear focus area in all our companies. Market conditions for introducing new products that improve the efficiency of research and healthcare processes are favourable. At the same time, we see that established product companies are increasingly moving towards distributor models, while companies with new and innovative technologies are seeking distribution partners. The pace of acquisitions has increased Following a period in which the main focus has been on organic improvement initiatives and strengthening the balance sheet, AddLife has now entered a new phase with increased acquisition activity. The number of acquisitions has increased from one per year in 2023 and 2024 to three in 2025. Lehnen was acquired in October, bringing the number of acquisitions to six over the past twelve-month period. Before the summer, CoaChrom and BioSpectrum were acquired, and during the past two months Unicam and Lehnen have been acquired. These companies meet our acquisition criteria well, operate within our prioritised product segments, and have margins that are clearly above our current average. We warmly welcome these companies to the AddLife family. For some time, we have strengthened our resources for driving acquisition processes and have established a clear allocation of responsibilities. A number of acquisition processes are being pursued in parallel, and we are working in a structured and long-term manner with our acquisition pipeline. Our decentralised model creates motivation, results and acquisition opportunities Decentralised responsibility is a very important part of our well-established and proven business model. The companies within AddLife retain their own brands and identity, while also having responsibility for their own strategy, operations and results. Quick decision-making processes and local mandates create motivated teams with a strong customer focus and a strong ability to quickly adapt to local markets and new trends. With the Group’s operations spread across Europe, the decentralised structure also contributes to natural resilience within the Group. AddLife | Interim report Q3 2026 2
Page 3
AddLife actively promotes decentralisation within its companies and, in recent years, has divided larger companies into more focused divisions and removed costly central functions. This has resulted in increased growth and improved margins. The decentralised model, combined with deep industry knowledge and an extensive network, also makes AddLife an attractive partner for entrepreneurs and a long-term home for successful companies. Summary and outlook The clear and evident positive development continues in AddLife’s companies, with strengthened margins, good growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, which has been prepared over an extended period. We now see a clearly increased pace of acquisitions and are pleased to welcome more new companies to the AddLife family. A warm thanks to all employees for valuable contributions and strong commitment. Development in our companies is positive and market trends are favourable. We look forward to building further on this during the fourth quarter of the year. Stockholm, October 21, 2026 Fredrik Dalborg President and CEO AddLife | Interim report Q3 2026 3
Page 4
GROUP DEVELOPMENT THIRD QUARTER Net sales increased by 7 percent to SEK 2,599 million (2,429). Organic growth amounted to 3 percent and acquired growth to 3 percent. Organic growth was negatively impacted by the divestment of the endoscopy operations in the United Kingdom in December 2025, corresponding to SEK 27 million. Adjusted for the divestment, organic growth amounted to 4 percent. Exchange rate effects had a positive impact on net sales of SEK 24 million, corresponding to 1 percent. Adjusted EBITA increased by 11 percent to SEK 298 million (270), corresponding to an adjusted EBITA margin of 11.5 percent (11.1). Adjusted EBITA excludes the remeasurement of contingent consideration of SEK 32 million. Exchange rate effects had a marginal impact on EBITA. Net financial items amounted to SEK -42 million (-54) and profit after financial items totalled SEK 179 million (111). Net financial items primarily include interest expenses related to the financing of previous acquisitions as well as exchange rate effects. Interest expenses amounted to SEK 46 million (47) and exchange rate gains to SEK 3 million (5). Profit after tax increased by 56 percent to SEK 128 million (82), and the effective tax rate was 28 percent (29). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses. Net sales quarter 2,429 75 71 24 2,599 Q3 2025 Organic Acquisitions Currency Q3 2026 2,400 2,450 2,500 2,550 2,600 2,650 EBITA quarter 270 5 20 3 32 330 Q3 2025 Organic Acquisitions Currency One-off costs Q3 2026 260 280 300 320 340 Net sales Quarter Rolling 12 months 2023 Q1 Q3 2024 Q1 Q3 2025 Q1 Q3 2026 Q1 Q3 1,000 1,500 2,000 2,500 3,000 6,000 8,000 10,000 12,000 Adjusted EBITA Quarter Rolling 12 months 2023 Q1 Q3 2024 Q1 Q3 2025 Q1 Q3 2026 Q1 Q3 150 200 250 300 350 600 800 1,000 1,200 1,400 AddLife | Interim report Q3 2026 4
Page 5
JANUARY – SEPTEMBER, 2026 Net sales increased by 3 percent to SEK 7,965 million (7,709). Growth, excluding exchange rate effects, amounted to 4 percent, of which organic growth was 2 percent and acquired growth was 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to SEK 120 million. Adjusted for the divestment, organic growth amounted to 4 percent. Exchange rate effects had a negative impact on net sales of SEK 89 million, corresponding to 1 percent. Adjusted EBITA increased by 6 percent to SEK 972 million (920), corresponding to an adjusted EBITA margin of 12.2 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent consideration of SEK 32 million. Currency effects had a negative impact on EBITA of SEK 9 million, corresponding to 1 percent. Net financial items amounted to SEK -135 million (-171) and profit after financial items totalled SEK 551 million (429). Net financial items mainly include interest expenses related to the financing of previous acquisitions as well as exchange rate fluctuations. Interest expenses amounted to SEK 133 million (156) and exchange rate losses to SEK 9 million (6). Profit after tax increased by 28 percent to SEK 386 million (302), and the effective tax rate was 30 percent (30). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses. Net sales January – September 7,709 160 185 -89 7,965 Jan-Sep, 2025 Organic Acquisitions Currency Jan-Sep, 2026 7,600 7,700 7,800 7,900 8,000 8,100 EBITA January – September 920 12 49 -9 32 1,004 Jan-Sep, 2025 Organic Acquisitions Currency One-off costs Jan-Sep, 2026 900 950 1,000 1,050 AddLife | Interim report Q3 2026 5
Page 6
Financial position and cash flow The equity ratio at the end of the interim period was 44 percent (43). Equity per share amounted to SEK 48.86 (44.67) and return on equity at the end of the interim period was 11 percent (11). Return on working capital (P/WC) was 63 percent (62). The Group’s net interest-bearing debt at the end of the interim period amounted to SEK 4,746 million (4,048), including pension liabilities of SEK 57 million (58), lease liabilities of SEK 571 million (504), contingent considerations corresponding to SEK 225 million (124) and provisions corresponding to SEK 27 million (29). Outstanding bank borrowings at the end of the interim period amounted to SEK 4,343 million (4,146), and were classified as current due to the remaining maturity. Subsequent to the end of the interim period, the company refinanced its existing bank facilities with a three-year term and two one-year extension options. Available liquidity, consisting of cash and bank balances, together with granted but unutilised credit facilities, amounted in total to SEK 1,450 million (1,447) at the end of the interim period. The net debt/equity ratio was 0.8, compared with 0.7 at the beginning of the year. Cash flow from operating activities amounted to SEK 236 million (145) during the quarter and to SEK 505 million (504) during the interim period. The increase during the quarter was primarily attributable to lower working capital tied up compared with the previous year. In total, the change in working capital during the quarter amounted to SEK -58 million (-143). During the interim period, payments for company acquisitions totalled SEK 377 million (164) and paid contingent considerations related to company acquisitions from previous years amounted to SEK 23 million (51). Net investments in non-current assets amounted to SEK 205 million (180), primarily related to investments in instruments placed with customers. A dividend of SEK 182 million (91) was paid to the Parent Company’s shareholders. Long term financial goals Profitability P/WC (%) Rolling 12 months Target 45% 2023 Ma… Jun 30 Sep 30 Dec 31 2024 Mar 31 Jun 30 Sep 30 Dec 31 2025 Mar 31 Jun 30 Sep 30 Dec 31 2026 Mar 31 Jun 30 Sep 30 0 25 50 75 Profit growth adjusted EBITA (%) Rolling 12 months Target 15% 2023 Mar … Jun 30 Sep 30 Dec 31 2024 Mar 31 Jun 30 Sep 30 Dec 31 2025 Mar 31 Jun 30 Sep 30 Dec 31 2026 Mar 31 Jun 30 Sep 30 -10 0 10 20 Employees At the end of the interim period, the number of employees was 2,428, compared to 2,295 at the beginning of the financial year. During the interim period, the completed acquisitions have led to an increase of 46 employees. The average number of employees for the last 12-month period was 2,336 (2,296). AddLife | Interim report Q3 2026 6
Page 7
Acquisitions Acquisitions completed from the 2025 financial year are distributed among the Group’s business areas as follows: Net Sales, Number of Company Country Time SEKm* employees* Business area Edge Medical Ltd. UK April 2025 90 20 Medtech Pharmacold A/S Denmark December 2025 38 20 Labtech Opitek International ApS Denmark December 2025 12 2 Medtech BioSpectrum Ltd. UK March 2026 75 16 Medtech CoaChrom Diagnostica GmbH Austria April 2026 110 10 Labtech Unicam Sistemas Analíticos Lda Portugal September 2026 110 20 Labtech 435 88 *Refers to conditions at the time of acquisition on a full-year basis. In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees. In April all shares in the Austrian company CoaChrom Diagnostica GmbH were acquired. CoaChrom is a distributor focusing on advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry. The company has annual sales of approximately EUR 10 million and 10 employees. In September, all shares in the Portuguese company Unicam Sistemas Analíticos Lda were acquired. Unicam distributes advanced analytical laboratory equipment to universities, research institutes and industrial customers. The company has annual revenue of approximately EUR 10 million and 20 employees. Net assets of acquired companies at the acquisition date Fair value Sep 30 SEKm 2026 Intangible non-current assets 183 Other non-current assets 11 Inventories 42 Other current assets 134 Deferred tax liability/tax asset -41 Other liabilities -82 Acquired net assets 247 Goodwill 337 Consideration¹ 584 Less: Cash and cash equivalents in acquired businesses -65 Contingent consideration not yet paid -142 Effect on the Group’s cash and cash equivalents 377 ¹The consideration is stated excluding acquisition expenses. Acquired companies The purchase price allocations are preliminary, as the net assets of the acquired companies have not yet been finally determined. For this year’s acquisitions, the purchase consideration exceeded the carrying amount of the net assets of the acquired companies, resulting in goodwill and intangible assets. Goodwill The goodwill arising from the acquisitions is attributable to the expectation that the Group’s position in the relevant markets will be strengthened, as well as the expertise developed in the acquired companies. Contingent consideration The contingent considerations included in the acquisitions are usually linked to the performance development of the respective companies. During the interim period, contingent consideration of SEK 23 million relating to acquisitions completed in previous years was paid to the sellers of BonsaiLab, Pharmacold and Opitek. Remeasurement of liabilities for contingent consideration relating to previous acquisitions resulted in a net income of SEK 32 million. These were reversed during the quarter and recognized in other operating income and expenses. Transaction costs Transaction costs for acquisitions amount to a total of SEK 5 million and are recognized in selling expenses. Revenue and earnings from acquired businesses The acquisitions completed during the year have, from their respective acquisition dates, contributed a total of SEK 114 million to the Group’s net sales and SEK 36 million to EBITA. Had the acquired companies been consolidated from January 1, 2026, net sales and EBITA would have amounted to SEK 293 million and SEK 91 million, respectively. Acquisitions after the end of the interim period In October, 85 percent of the shares in the German company Lehnen GmbH were acquired. Lehnen manufactures products and system solutions for accessible and functionally adapted bathrooms. The company has annual sales of approximately EUR 5 million and around 30 employees. AddLife | Interim report Q3 2026 7
Page 8
BUSINESS AREA The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe. Q3 Q3 ∆ Jan-Sep Jan-Sep ∆ Oct 2025- Full year SEKm 2026 2025 % 2026 2025 % Sep 2026 2025 Net sales 983 906 8 3,025 2,880 5 4,098 3,953 Organic growth, % 2 9 2 9 5 EBITA 115 102 14 386 343 12 538 495 EBITA margin, % 11.7 11.2 12.8 11.9 13.1 12.5 Adjusted EBITA 126 102 24 397 343 16 549 495 Adjusted EBITA margin, % 12.9 11.2 13.1 11.9 13.4 12.5 Labtech THIRD QUARTER Net sales in Labtech increased by 8 percent to 983 million (906). Organic growth amounted to 2 percent and acquired growth to 5 percent. Exchange rate effects had a positive impact on net sales of SEK 10 million, corresponding to 1 percent. Adjusted EBITA increased by 24 percent to SEK 126 million (102), corresponding to an adjusted EBITA margin of 12.9 percent (11.2). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK -11 million. Exchange rate effects had a positive impact of SEK 2 million on EBITA, corresponding to 2 percent. JANUARY – SEPTEMBER, 2026 Labtech’s net sales increased by 5 percent to SEK 3,025 million (2,880). Adjusted for exchange rate effects, net sales increased by 6 percent, of which organic growth increased by 2 percent and acquired growth amounted to 4 percent. Exchange rate effects had a negative impact on net sales of SEK 20 million, corresponding to 1 percent. Adjusted EBITA increased by 16 percent to SEK 397 million (343), corresponding to an adjusted EBITA margin of 13.1 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK -11 million. Exchange rate effects had a negative impact of SEK 1 million on EBITA, corresponding to 0 percent. Net sales quarter 906 17 50 10 983 Q3 2025 Organic Acquisitions Currency Q3 2026 900 920 940 960 980 1,000 Net sales January – September 2,880 63 102 -20 3,025 Jan-Sep, 2025 Organic Acquisitions Currency Jan-Sep, 2026 2,800 2,850 2,900 2,950 3,000 3,050 AddLife | Interim report Q3 2026 8
Page 9
Labtech performed well during the quarter, both organically and with a clear contribution from acquisitions. Within diagnostics, demand remained stable and strong, particularly in blood gas analysis, pathology, point-of-care testing, molecular diagnostics, automation, service and specialized coagulation. Within research, activity was seasonally lower during the summer, primarily due to a lower level of instrument deliveries. Development in Eastern Europe remained strong, driven by solid underlying market growth and investments in advanced technology. Several new products were added to the portfolio during the quarter, including products within immunohematology and transfusion medicine, which are expected to contribute to further growth going forward. The business in Southern Europe was strengthened through the acquisition of Unicam, a distributor of advanced laboratory equipment to universities, research institutes and industrial customers. Net sales Quarter Rolling 12 months 2023 Q1 Q3 2024 Q1 Q3 2025 Q1 Q3 2026 Q1 Q3 600 750 900 1,050 1,200 2,000 2,500 3,000 3,500 4,000 4,500 Net sales per market January – September 2026 Sweden, 17% Italy, 12% Denmark, 11% Norway, 9% Finland, 9% Austria, 4% Czech Republic, 4% Germany, 4% Poland, 4% Netherlands, 3% Rest of Europe, 20% Rest of the World, 3% Adjusted EBITA Quarter Rolling 12 months 2023 Q1 Q2 Q3 Q4 2024 Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 Q1 Q2 Q3 0 50 100 150 200 150 300 450 600 Adjusted EBITA margin (%) Quarter, % Rolling 12 months, % 2023 Q1 Q2 Q3 Q4 2024 Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 Q1 Q2 Q3 6 8 10 12 14 16 6 8 10 12 14 16 AddLife | Interim report Q3 2026 9
Page 10
BUSINESS AREA In the Medtech business area, the subsidiaries offer products and services in the field of medical technology, as well as assistive equipment and digital solutions for home care. Medtech has two business units, Hospital and Homecare. The Medtech offering mainly focuses on publicly funded healthcare, home care and social care in Europe. Q3 Q3 ∆ Jan-Sep Jan-Sep ∆ Oct 2025- Full year SEKm 2026 2025 % 2026 2025 % Sep 2026 2025 Net sales 1,617 1,524 6 4,944 4,832 2 6,607 6,495 Organic growth, % 4 4 2 2 2 EBITA 226 177 27 651 607 7 1,008 964 EBITA margin, % 14.0 11.6 13.2 12.6 15.3 14.8 Adjusted EBITA 183 177 3 608 607 0 806 805 Adjusted EBITA margin, % 11.3 11.6 12.3 12.6 12.2 12.4 Medtech THIRD QUARTER Net sales in Medtech increased by 6 percent to SEK 1,617 million (1,524). Organic growth amounted to 4 percent and acquired growth to 1 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to approximately SEK 27 million. Adjusted for the divestment, organic growth amounted to 5 percent. Exchange rate effects had a positive impact on net sales of SEK 17 million, corresponding to 1 percent. Adjusted EBITA increased by 3 percent to SEK 183 million (177), corresponding to an adjusted EBITA margin of 11.3 percent (11.6). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK 43 million. Exchange rate effects had a positive impact on EBITA of SEK 2 million, corresponding to 1 percent. JANUARY – SEPTEMBER, 2026 Medtech’s net sales amounted to SEK 4,944 million (4,832). Adjusted for exchange rate effects, net sales increased by 4 percent, of which organic growth amounted to 2 percent and acquired growth to 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to approximately SEK 120 million. Adjusted for the divestment, organic growth amounted to 5 percent. Exchange rate effects had a negative impact on net sales of SEK 68 million, corresponding to 1 percent. Adjusted EBITA increased marginally to SEK 608 million (607), corresponding to an adjusted EBITA margin of 12.3 percent (12.6). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK 43 million. Exchange rate effects had a negative impact on EBITA of SEK 9 million, corresponding to 1 percent. Net sales quarter 1,524 55 21 17 1,617 Q3 2025 Organic Acquisitions Currency Q3 2026 1,500 1,525 1,550 1,575 1,600 1,625 1,650 Net sales January – September 4,832 97 83 -68 4,944 Jan-Sep, 2025 Organic Acquisitions Currency Jan-Sep, 2026 4,750 4,800 4,850 4,900 4,950 5,000 5,050 AddLife | Interim report Q3 2026 10
Page 11
Medtech grew in line with the market during the quarter, with acquisitions also contributing to growth. The number of planned surgical procedures is normally lower during the summer months, which was also the case this year, particularly within hospital products and ophthalmic surgery. Growth in the Nordic region was good. In Spain, development continued to be affected by the impact of healthcare labor disputes, but growth remained good in spite of this. In the UK, the number of surgical procedures performed increased compared with the previous year, while capital equipment ordered during the previous quarter was delivered. Homecare continues to develop well. Through the acquisition of Lehnen, the business outside the Nordics is strengthened and the portfolio is expanded with additional in-house manufactured products. Net sales Quarter Rolling 12 months 2023 Q1 Q3 2024 Q1 Q3 2025 Q1 Q3 2026 Q1 Q3 1,200 1,300 1,400 1,500 1,600 1,700 1,800 2,000 3,000 4,000 5,000 6,000 7,000 8,000 Adjusted EBITA Quarter Rolling 12 months 2023 Q1 Q3 2024 Q1 Q3 2025 Q1 Q3 2026 Q1 Q3 0 50 100 150 200 250 200 400 600 800 1,000 Net sales per market January– September 2026 Ireland, 20% UK, 19% Spain, 15% Sweden, 9% Norway, 7% Switzerland, 5% Germany, 5% Denmark, 4% Finland, 3% Italy, 3% Austria, 2% Rest of Europe, 7% Rest of the World, 1% Adjusted EBITA margin (%) Quarter, % Rolling 12 months, % 2023 Q1 Q2 Q3 Q4 2024 Q1 Q2 Q3 Q4 2025 Q1 Q2 Q3 Q4 2026 Q1 Q2 Q3 6 8 10 12 14 6 8 10 12 14 AddLife | Interim report Q3 2026 11
Page 12
Decentralisation is part of our DNA AddLife’s business model is based on local entrepreneurship, clear responsibility and proximity to customers and suppliers. Our decentralised structure gives the subsidiaries the freedom to develop their operations based on local market conditions and their own strengths, while benefiting from the Group’s experience, network and financial stability. Decentralisation is part of our DNA and characterises how we build and develop our companies over time. In recent years, we have simplified structures, moved responsibility closer to the operations and clarified responsibility for business performance. This has created a more focused and business-oriented organisation with better conditions for organic growth, more efficient capital use and improved margins. The development is evident in several of our larger platforms. Within HC21, operations in the UK and Ireland have been given clearer local responsibility. Within MBA, a previously shared commercial organisation has been split into three specialised divisions: Within AddVision, the central Group functions have been discontinued, and responsibility has been transferred to five local companies. Our decentralised model is a strength in our acquisition activities. With a clear acqusition responsibility given to the business unit leaders, acquisition activities move closer to the market and strengthen our ability to identify and develop companies that fit AddLife’s culture, selected niches and long-term growth ambitions. Together, local entrepreneurship, clear responsibility for business performance and active Group support contribute to a more efficient and motivated organisation. This strengthens AddLife and creates good conditions for continued profitable growth. Value for AddLife and the subsidiaries The subsidiaries have the freedom to act close to customers and suppliers, while benefiting from the Group’s strength, network and experience. M&A is driven by the responsible business unit leaders, with support from experienced advisers and resources from the subsidiaries. Decentralisation attracts and retains talent. The decentralised model is motivating for team members, offers growth opportunities and attracts individuals and acquisition targets. MBA SURGICAL EMPOWERMENT From one commercial organisation to three specialised divisions: Orthopaedics & Trauma; Neuro, Oncology, Spine & Biologics; and Anaesthesia & Surgery. O N A HC21 YOUR TRUSTED MEDTECH PARTNER From a joint organisation for the UK and Ireland to country- specific organisations with specialised commercial divisions. UK IE AddVision BRINGING GREATER VISION TO EVERYONE From central Group functions to five local companies: one in Poland, one in Switzerland, one in the UK and two in Germany. DE DE PL UKCH AddLife | Interim report Q3 2026 12
Page 13
FINANCIAL INFORMATION BY BUSINESS AREA Net sales by business area 2024 2025 2026 SEKm Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Labtech 852 1,141 989 985 906 1,073 985 1,057 983 Medtech 1,494 1,679 1,714 1,594 1,524 1,663 1,661 1,666 1,617 Group items -2 -2 -1 -1 -1 -3 -1 -2 -1 The Group 2,344 2,818 2,702 2,578 2,429 2,733 2,645 2,721 2,599 EBITA by business area 2024 2025 2026 SEKm Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Labtech 76 161 120 122 102 152 129 142 115 Medtech 153 195 231 198 177 357 212 213 226 Group items -6 -10 -8 -13 -9 -12 -9 -13 -11 The Group 223 346 343 307 270 497 332 342 330 2024 2025 2026 % Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Labtech 8.9 14.1 12.1 12.4 11.2 14.1 13.1 13.4 11.7 Medtech 10.3 11.6 13.5 12.4 11.6 21.5 12.8 12.8 14.0 The Group 9.5 12.3 12.7 11.9 11.1 18.2 12.5 12.6 12.7 Adjusted EBITA / Adjusted EBITA margin by business area 2024 2025 2026 SEKm Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Labtech 76 161 120 122 102 152 129 142 126 Medtech 160 195 231 198 177 199 212 213 183 Group items -6 -10 -8 -13 -9 -12 -9 -13 -11 The Group 230 346 343 307 270 339 332 342 298 2024 2025 2026 % Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Labtech 8.9 14.1 12.1 12.4 11.2 14.1 13.1 13.4 12.9 Medtech 10.7 11.6 13.5 12.4 11.6 12.0 12.8 12.8 11.3 The Group 9.8 12.3 12.7 11.9 11.1 12.4 12.5 12.6 11.5 Quarterly data AddLife | Interim report Q3 2026 13
Page 14
Net sales by business area Q3 Q3 ∆ Jan-Sep Jan-Sep ∆ Oct 2025- Full year SEKm 2026 2025 % 2026 2025 % Sep 2026 2025 Labtech 983 906 8 3,025 2,880 5 4,098 3,953 Medtech 1,617 1,524 6 4,944 4,832 2 6,607 6,495 Group items -1 -1 -4 -3 -7 -6 The Group 2,599 2,429 7 7,965 7,709 3 10,698 10,442 EBITA / EBITA margin by business area and operating profit for the Group Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Labtech 115 102 386 343 538 495 Medtech 226 177 651 607 1,008 964 Group items -11 -9 -33 -30 -45 -42 EBITA 330 270 1,004 920 1,501 1,417 Depreciation and write-down intangible assets -109 -105 -318 -320 -422 -424 Operating profit 221 165 686 600 1,079 993 Finance income and expenses -42 -54 -135 -171 -185 -221 Profit after financial items 179 111 551 429 894 772 Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year % 2026 2025 2026 2025 Sep 2026 2025 Labtech 11.7 11.2 12.8 11.9 13.1 12.5 Medtech 14.0 11.6 13.2 12.6 15.3 14.8 EBITA margin 12.7 11.1 12.6 11.9 14.0 13.6 Operating margin 8.5 6.8 8.6 7.8 10.1 9.5 Net sales by revenue type Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Products 681 631 2,148 2,066 2,877 2,795 Instruments 218 189 633 579 898 844 Services 84 86 244 235 323 314 Labtech 983 906 3,025 2,880 4,098 3,953 Products 1,338 1,258 4,111 3,974 5,499 5,362 Instruments 115 102 349 377 465 493 Services 164 164 484 481 643 640 Medtech 1,617 1,524 4,944 4,832 6,607 6,495 Group items -1 -1 -4 -3 -7 -6 The Group 2,599 2,429 7,965 7,709 10,698 10,442 Net sales and EBITA AddLife | Interim report Q3 2026 14
Page 15
Sales per country Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Ireland 352 328 1,009 996 1,343 1,330 Sweden 306 299 966 896 1,296 1,226 UK 320 290 933 945 1,238 1,250 Spain 231 235 805 799 1,084 1,078 Norway 179 178 622 629 821 828 Denmark 163 157 511 489 703 681 Italy 141 170 510 563 678 731 Finland 145 129 436 397 595 556 Germany 127 114 362 339 478 455 Switzerland 98 87 310 289 401 380 Rest of Europe 513 393 1,312 1,143 1,870 1,701 Rest of the World 24 49 189 224 191 226 Total 2,599 2,429 7,965 7,709 10,698 10,442 32% 18% 2% SOUTHERN EUROPE REST OFTHE WORLD NORDICS 10 % 38 % WESTERN EUROPE CENTRAL & EASTERN EUROPE Sales by region January – September 2026 AddLife | Interim report Q3 2026 15
Page 16
FINANCIAL INFORMATION Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Net sales 2,599 2,429 7,965 7,709 10,698 10,442 Cost of sales -1,600 -1,521 -4,869 -4,773 -6,561 -6,465 Gross profit 999 908 3,096 2,936 4,137 3,977 Selling expenses -647 -589 -1,937 -1,867 -2,599 -2,529 Administrative expenses -157 -145 -497 -447 -661 -611 Research and Development -14 -14 -44 -43 -58 -57 Other operating income and expenses 40 5 68 21 260 213 Operating profit 221 165 686 600 1,079 993 Financial income and expenses -42 -54 -135 -171 -185 -221 Profit after financial items 179 111 551 429 894 772 Tax -51 -29 -165 -127 -248 -210 Profit for the period 128 82 386 302 646 562 Attributable to: Equity holders of the Parent Company 127 81 384 300 644 560 Non-controlling interests 1 1 2 2 2 2 Earnings per share before dilution, SEK 1.05 0.66 3.15 2.47 5.28 4.59 Earnings per share after dilution, SEK 1.05 0.66 3.15 2.47 5.28 4.59 Average number of shares after repurchases, '000s 121,864 121,864 121,864 121,864 121,864 121,864 Number of shares at end of the period, '000 121,864 121,864 121,864 121,864 121,864 121,864 EBITA 330 270 1,004 920 1,501 1,417 Depreciations and write-down included in operating expenses: Property, plant and equipment -101 -94 -287 -280 -392 -385 Intangible non-current assets from acquisitions -98 -93 -283 -288 -375 -380 Other intangible non-current assets -11 -12 -35 -32 -47 -44 Condensed consolidated income statement Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Profit for the period 128 82 386 302 646 562 Components that may be reclassified to profit for the period: Foreign currency translation differences for the period 133 -43 304 -213 178 -339 Components that can not be reclassified to profit for the period: Revaluations of defined benefit pension plans – – – – 4 4 Tax attributable to items not to be reversed in profit or loss – – – – -1 -1 Other comprehensive income 133 -43 304 -213 181 -336 Total comprehensive income 261 39 690 89 827 226 Attributable to: Equity holders of the Parent Company 260 37 688 87 824 223 Non-controlling interests 1 2 2 2 3 3 Consolidated statement of comprehensive income AddLife | Interim report Q3 2026 16
Page 17
Sep 30 Sep 30 Dec 31 SEKm 2026 2025 2025 Goodwill 6,041 5,523 5,449 Other intangible non-current assets 1,982 2,089 1,998 Property, plant and equipment 1,222 1,123 1,089 Financial non-current assets 48 30 26 Total non-current assets 9,293 8,765 8,562 Inventories 1,933 1,724 1,652 Current receivables 1,922 1,885 1,684 Cash and cash equivalents 477 286 813 Total current assets 4,332 3,895 4,149 Total assets 13,625 12,660 12,711 Total equity 5,958 5,308 5,447 Interest-bearing provisions 84 91 87 Non-interest-bearing provisions 344 332 324 Non-current interest-bearing liabilities 516 2,884 2,831 Non-current non-interest-bearing liabilities 34 32 31 Total non-current liabilities 978 3,339 3,273 Non-interest-bearing provisions 52 45 51 Current interest-bearing liabilities 4,623 2,132 1,943 Current non-interest-bearing liabilities 2,014 1,836 1,997 Total current liabilities 6,689 4,013 3,991 Total equity and liabilities 13,625 12,660 12,711 Condensed consolidated balance sheet Jan 1 – Sep 30, 2026 Jan 1 – Dec 31, 2025 SEKm Equity excl. non- controlling interests Non-controlling interests Total equity Equity excl. non- controlling interests Non-controlling interests Total equity Amount at beginning of period 5,443 4 5,447 5,306 3 5,309 Share-based payments 5 – 5 5 – 5 Dividend -182 -2 -184 -91 -2 -93 Total comprehensive income 688 2 690 223 3 226 Amount at the end of the period 5,954 4 5,958 5,443 4 5,447 Condensed consolidated statement of changes in equity AddLife | Interim report Q3 2026 17
Page 18
Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Operating profit 221 165 686 600 1,079 993 Adjustment for items not included in cash flow 148 193 525 570 740 785 Interest paid -46 -47 -131 -156 -177 -202 Interest received 9 – 14 1 17 4 Income tax paid -38 -23 -154 -114 -257 -217 Changes in working capital -58 -143 -435 -397 -9 29 Cash flow from operating activities 236 145 505 504 1,393 1,392 Net investments in non-current assets -73 -58 -205 -180 -279 -254 Acquisitions and disposals -77 -26 -400 -215 -432 -247 Change in other financial assets 1 0 0 0 4 4 Cash flow from investing activities -149 -84 -605 -395 -707 -497 Dividend paid to shareholders – – -182 -91 -182 -91 Dividend paid to non-controlling interests -2 – -2 -2 -2 -2 Borrowings/repayment of borrowings, net -1 32 -1 139 -170 -30 Repayments on lease liability -50 -45 -144 -137 -189 -182 Other financing activities 1 0 2 0 2 0 Cash flow from financing activities -52 -13 -327 -91 -541 -305 Cash flow for the period 35 48 -427 18 145 590 Cash and cash equivalents at beginning of period 394 253 813 331 286 331 Exchange differences on cash and cash equivalents 48 -15 91 -63 46 -108 Cash and cash equivalents at end of the period 477 286 477 286 477 813 Condensed consolidated statement of cash flows AddLife | Interim report Q3 2026 18
Page 19
Rolling 12 months ending Sep 30 Dec 31 Sep 30 Dec 31 Dec 31 2026 2025 2025 2024 2023 Net sales, SEKm 10,698 10,442 10,527 10,286 9,685 EBITDA, SEKm 1,893 1,802 1,644 1,533 1,504 EBITA, SEKm 1,501 1,417 1,266 1,159 1,135 EBITA margin, % 14.0 13.6 12.0 11.3 11.7 Adjusted EBITA, SEKm 1,311 1,259 1,266 1,165 1,015 Adjusted EBITA margin, % 12.3 12.1 12.0 11.3 10.5 Profit growth EBITA, % 19 22 16 2 -7 Profit growth adjusted EBITA, % 4 8 18 14 -10 Return on working capital (P/WC), % 63 62 55 51 50 Profit for the period, SEKm 646 562 396 254 192 Return on equity, % 11 11 8 5 4 Financial net liabilities, SEKm 4,746 4,048 4,821 4,920 5,192 Financial net liabilities/EBITDA, multiple 2.5 2.2 2.9 3.2 3.5 Net debt/equity ratio, multiple 0.8 0.7 0.9 0.9 1.0 Equity ratio, % 44 43 42 41 39 Average number of employees 2,336 2,292 2,296 2,311 2,284 Number of employees at end of the period 2,428 2,295 2,327 2,256 2,300 Key ratios per share Attributable to owners of the parent Sep 30 Dec 31 Sep 30 Dec 31 Dec 31 2026 2025 2025 2024 2023 Earnings per share (EPS), before dilution, SEK¹ 5.28 4.59 3.23 2.06 1.56 Earnings per share (EPS), after dilution, SEK¹ 5.28 4.59 3.23 2.06 1.56 Cash flow per share from operating activities, SEK¹ 11.43 11.42 9.59 8.98 6.35 Shareholders' equity per share, SEK 48.86 44.67 43.53 43.54 40.69 Average number of shares after repurchases, '000s¹ 121,864 121,864 121,864 121,863 121,856 Average number of shares adjusted for repurchases and dilution, '000s¹ 121,870 121,884 121,872 121,863 121,861 Number of shares outstanding at end of the period, '000s 121,864 121,864 121,864 121,864 121,857 Number of shares outstanding at end of the period after dilution, '000s 121,870 121,884 121,872 121,864 121,857 ¹Presented in rolling 12 months Definitions can be found here. Key figures AddLife | Interim report Q3 2026 19
Page 20
Parent company The Parent Company’s net sales for the interim period amounted to SEK 58 million (54) and profit after financial items totalled SEK -169 million (165). The Parent Company’s net financial debt at the end of the interim period amounted to SEK 4,310 million (3,740). Share capital at the end of the interim period amounted to SEK 62 million (62). Parent Company condensed income statement Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Net sales 21 18 58 54 84 80 Administrative expenses -28 -26 -91 -86 -122 -117 Operating profit -7 -8 -33 -32 -38 -37 Interest income/expenses and similar items -72 56 -136 197 -39 294 Profit after financial items -79 48 -169 165 -77 257 Appropriations – – – – -159 -159 Profit/loss before taxes -79 48 -169 165 -236 98 Tax – -4 – -19 19 0 Profit for the period -79 44 -169 146 -217 98 Parent Company condensed balance sheet Sep 30 Sep 30 Dec 31 SEKm 2026 2025 2025 Intangible non-current assets 0 0 0 Property, plant and equipment 0 0 0 Financial non-current assets 7,888 8,019 8,246 Total non-current assets 7,888 8,019 8,246 Current receivables 361 507 504 Cash and cash equivalents 22 – 395 Total current assets 383 507 899 Total assets 8,271 8,526 9,145 Restricted equity 62 62 62 Unrestricted equity 2,315 2,708 2,661 Total equity 2,377 2,770 2,723 Non-current interest-bearing liabilities 45 2,501 2,449 Non-current non-interest-bearing liabilities 3 2 3 Total non-current liabilities 48 2,503 2,452 Current interest-bearing liabilities 5,812 3,205 3,570 Current non-interest-bearing liabilities 34 48 400 Total current liabilities 5,846 3,253 3,970 Total equity and liabilities 8,271 8,526 9,145 AddLife | Interim report Q3 2026 20
Page 21
OTHER INFORMATION Accounting policies The interim report has been prepared in accordance with IFRS Accounting Standards, applying IAS 34 Interim Financial Reporting. Disclosures according to IAS 34.16A are presented not only in the financial statements and accompanying notes but also in other parts of the interim report. The Parent Company's interim report has been prepared in accordance with the Swedish Annual Accounts Act and the Securities Market Act which is in compliance with recommendation RFR 2 Accounting for Legal Entities. The same accounting principles and calculation methods as in AddLife's 2025 annual report have been applied in this interim report. Comparative figures in the interim period for income statement items refer to the value for the period January – September, 2025 and for balance sheet items as of December 31, 2025, unless otherwise stated. New or amended accounting policies from 2026 onwards IFRS 18 and related amendments to other standards shall be applied for financial years beginning on or after 1 January 2027, with retrospective application. The new standard, which has been adopted by the EU, replaces IAS 1. The standard does not affect the recognition or measurement of items in the financial statements, but only results in changes to presentation and disclosures. An analysis of the effects of the standard on the Group is in progress. The standard has not been early adopted. No other new or amended accounting standards or interpretations approved for application from 2026 are assessed to have any material effect on the Group’s financial statements. Information on Global Minimum Tax The Group is subject to the OECD’s Pillar II Model Rules. The Group’s exposure to the Pillar II legislation has been calculated and analysed. The Group’s assessment is that Pillar II has no material impact on the third quarter of 2026. Risks and uncertainties The geopolitical situation in Ukraine and the Middle East has not had any material direct impact on AddLife’s financial reports during the interim period. However, continued geopolitical and trade policy uncertainty may indirectly affect the availability of products and components, supply chains, freight and energy costs, as well as public healthcare and research budgets. AddLife’s operations are primarily European, with approximately 95 percent of sales and 80 percent of purchases taking place in Europe, which limits direct exposure. At the same time, subcontractors and components further down the supply chain may be affected by tariffs, trade barriers, sanctions and international transport disruptions. AddLife closely monitors developments relating to trade barriers, inflation, raw material, component, energy and freight costs, interest rates, as well as effects on customer demand and willingness to invest. For further information, reference is made to the section "Risks and uncertainties" in the administration report in AddLife’s 2025 Annual Report. The Parent Company is indirectly affected by the above risks and uncertainties through its function within the Group. Transactions with related parties No related party transactions have taken place during the interim period that have had a material impact on the Group’s financial position or results. AddLife | Interim report Q3 2026 21
Page 22
Sep 30, 2026 Dec 31, 2025 Carrying Carrying SEKm amount Level 2 Level 3 amount Level 2 Level 3 Derivatives measured at fair value through profit or loss 0 0 – 0 0 – Total financial assets at fair value per level 0 0 – 0 0 – Derivatives measured at fair value through profit or loss 0 0 – 0 0 – Contingent considerations 225 – 225 124 – 124 Total financial liabilities at fair value per level 225 0 225 124 0 124 Contingent considerations Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Amount at beginning of period 227 107 124 106 106 106 Acquisitions during the period 28 – 142 54 162 74 Consideration paid -3 – -23 -51 -23 -51 Revaluation through profit or loss -33 – -32 – -32 – Interest expenses 1 1 3 2 4 3 Exchange differences 5 -2 11 -5 8 -8 Amount at the end of the period 225 106 225 106 225 124 Financial instruments Fair values on financial instruments Fair value and carrying amount are recognised in the balance sheet as shown in the table below. For quoted securities, the fair value is determined on the basis of the asset’s quoted price in an active market, level 1. At the reporting date, the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash flow-based valuation is performed, which is not based on observable market data, level 3. For the Group’s other financial assets and liabilities, fair value is estimated to essentially correspond to the carrying amount. Sep 30 Sep 30 Dec 31 SEKm 2026 2025 2025 Contingent liabilities 49 52 50 Pledged assets and contingent liabilities Nomination Committee At the 2026 Annual General Meeting, it was resolved to authorize the Chairman of the Board to appoint, from among representatives of the five largest shareholders in terms of voting rights as of September 30, 2026, members who, together with the Chairman, shall constitute the Nomination Committee ahead of the forthcoming Board election. In accordance with this, the following persons have been appointed as members of the Nomination Committee: Johan Sjö, Chairman of the Board, Stefan Hedelius (appointed by Tom Hedelius), Håkan Roos (appointed by RoosGruppen AB), Roger Hedberg (appointed by Cliens Kapitalförvaltning), Andreas Wallheim (appointed by SEB Fonder), and Erik Eikeland (appointed by AMF Fonder). Information on how to contact the Nomination Committee is available on AddLife’s website; add.life/investors/corporate-governance. AddLife | Interim report Q3 2026 22
Page 23
Significant events after the end of the interim period Acquisition In October, 85 percent of the shares in the German company Lehnen GmbH were acquired. Lehnen manufactures products and system solutions for accessible and functionally adapted bathrooms. The company has annual sales of approximately EUR 5 million and around 30 employees. Bank loans In October, the existing bank facilities were refinanced with a three-year term and two one-year extension options. Stockholm, October 21, 2026 Fredrik Dalborg President and CEO AddLife | Interim report Q3 2026 23
Page 24
Auditor’s report To the Board of Directors in AddLife AB (publ), corporate identity number 556995-8126 Introduction We have conducted a limited review of the condensed interim financial information (interim report) for AddLife AB (publ) as of September 30, 2026, and the nine-month period ending on that date. The Board of Directors and the managing director are responsible for preparing and presenting this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our limited review. The focus and scope of the limited review We have conducted our limited review in accordance with the International Standard on Review Engagements ISRE 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A limited review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical procedures, and other review procedures. A limited review has a different focus and a significantly smaller scope compared to the focus and scope of an audit conducted in accordance with ISA and generally accepted auditing standards. The review procedures taken in a limited review do not enable us to obtain the assurance that we would become aware of all significant matters that might have been identified in an audit. Therefore, the conclusion expressed based on a limited review does not have the assurance that a conclusion expressed based on an audit has. Conclusion Based on our limited review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the group in accordance with IAS 34 and the Annual Accounts Act and for the parent company in accordance with the Annual Accounts Act. Stockholm, October 21, 2026 Öhrlings PricewaterhouseCoopers AB Fredrik Göransson Authorized Public Accountant AddLife | Interim report Q3 2026 24
Page 25
Number of employees at the end of the period The number of employees in the Group at the end of the reporting period, taking into account the degree of employment. This measure is used to know how many employees the Group has at the end of the reporting period. Return on equity Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity. Return on equity measures from an ownership perspective the return that is given on the owners' invested capital. Return on working capital (P/WC) EBITA in relation to average working capital. P/WC is used to analyse profitability and encourage high EBITA earnings and low working capital requirements. EBITA Operating profit before amortisation and write-down of intangible assets. EBITA is used to assess operating profitability excluding the impact of amortisation and impairment of intangible assets, primarily arising from acquisitions. EBITA margin EBITA as a percentage of net sales. The EBITA margin is used to analyze value creation from the operating activities. EBITDA Operating profit before depreciation, amortisation and write-down. EBITDA is used to assess earnings generation before depreciation, amortisation and impairment, and as a measure closely reflecting operating cash flow before changes in working capital and investments. Equity per share Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period. Financial net Financial income minus financial expenses. Used to describe the development of the Group's financial activities. Acquired growth Changes in net sales attributable to business acquisitions compared to the same period the previous year. Acquired growth is used as a component to describe the development of the Group's net sales, where acquired growth is distinguished from organic growth, divestments, and currency effects. Adjusted EBITA EBITA excluding one-off costs. Increases the comparability of EBITA over time as it is adjusted for the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations. Adjusted EBITA margin Adjusted EBITA in relation to net sales. Used to measure the company's profitability excluding the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations. One-off costs Primarily refers to restructuring costs and revaluation of contingent considerations. Other non-recurring items may also be reported as one-off costs if this provides a more accurate view of the underlying operating result. Definitions AddLife | Interim report Q3 2026 25
Page 26
Cash flow from operating activities per share Cash flow from operating activities, divided by the average number of shares. The measure is used to allow investors to easily analyze the amount of surplus from ongoing operations generated per share. Net investments in fixed assets Investments in fixed assets minus sales of fixed assets. The measure is used to analyze the Group's investments in the renewal and development of tangible fixed assets. Net debt/equity ratio Financial net liabilities in relation to shareholders’ equity. Net debt/equity ratio is used to analyse financial risk. Organic growth Changes in net sales excluding currency effects and acquisitions/divestments compared to the same period the previous year. Organic growth is used to analyze the underlying sales growth driven by changes in volume, product range, and price for similar products between different periods. Profit after financial items Profit/loss for the period before tax. Used to analyse the business’ profitability including financial activities Earnings per share Shareholders' share of the period's result divided by the number of shares outstanding at the end of the reporting period. Earnings per share before dilution Shareholders' share of the period's result divided by the average number of outstanding shares. Earnings per share after dilution Shareholders' share of the period's result divided by a weighted average of the number of outstanding shares, adjusted for the additional number of shares upon the exercise of outstanding options. Profit growth EBITA The period's EBITA decreased by previous period's EBITA divided by the previous period's EBITA. Profit growth EBITA is used to analyse asset-creating generated from operational activities. Financial net liabilities Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents. Net debt is used to monitor debt development and analyse financial leverage and any necessary refinancing. Financial net liabilities/EBlTDA Financial net liabilities divided by EBITDA. Financial net liabilities compared with EBITDA provides a key financial indicator for financial net liabilities in relation to cash-generated operating profit; i.e., an indication of the ability of the business to pay its debts. This measure is generally used by financial institutions as a measure of creditworthiness. Working capital Sum of inventories and accounts receivable, less accounts payable. In the calculation of P/WC, average working capital is used. Working capital is used to analyse how much working capital is tied up in the business. Equity ratio Equity, including non-controlling interests, as a percentage of total assets. The equity ratio is used to analyse financial risk and shows how much of the assets are financed with equity. AddLife | Interim report Q3 2026 26
Page 27
Return on equity Sep 30 Sep 30 Full year SEKm 2026 2025 2025 Profit/loss for the period attributable to shareholders (rolling 12 months) 644 394 560 Average equity 5,612 5,232 5,293 Return on equity, % 11 8 11 Return on working capital (P/WC) Sep 30 Sep 30 Full year SEKm 2026 2025 2025 EBITA (rolling 12 months) 1,501 1,266 1,417 Inventories, average 1,771 1,746 1,713 Accounts receivable, average 1,613 1,579 1,586 Accounts payable, average -1,005 -1,016 -1,013 Working capital, average 2,379 2,309 2,286 Return on working capital, % 63 55 62 EBITA and EBITDA Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 Operating profit 221 165 686 600 1,079 993 Amortisation and impairment of intangible assets 109 105 318 320 422 424 EBITA 330 270 1,004 920 1,501 1,417 Depreciation and impairment of tangible assets 101 94 287 280 392 385 EBITDA 431 364 1,291 1,200 1,893 1,802 Adjusted EBITA Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 EBITA 330 270 1,004 920 1,501 1,417 One-off costs Sale of business – – – – -158 -158 Revalued contingent consideration -32 – -32 – -32 – Adjusted EBITA 298 270 972 920 1,311 1,259 Alternative performance measures This report contains financial key figures in accordance with the frameworks applied by AddLife, which are based on IFRS. In addition, there are alternative performance measures (APM) that cannot be directly extracted or derived from the financial statements. These key figures are essential for understanding and evaluating AddLife's operations and financial position. They should not be seen as a replacement for the measures defined according to IFRS but rather as a complement to the financial reporting. Since not all companies calculate financial measures in the same way, these are not always comparable with measures used by other companies. The key figures are presented below and commented on in other parts of the interim period. AddLife | Interim report Q3 2026 27
Page 28
EBITA margin / Adjusted EBITA margin Q3 Q3 Jan-Sep Jan-Sep Oct 2025- Full year SEKm 2026 2025 2026 2025 Sep 2026 2025 EBITA 330 270 1,004 920 1,501 1,417 Net sales 2,599 2,429 7,965 7,709 10,698 10,442 EBITA margin, % 12.7 11.1 12.6 11.9 14.0 13.6 Adjusted EBITA 298 270 972 920 1,311 1,259 Adjusted EBITA margin, % 11.5 11.1 12.2 11.9 12.3 12.1 Organic growth Labtech Medtech The Group¹ Q3 Q3 Q3 Q3 Q3 Q3 % 2026 2025 2026 2025 2026 2025 Total growth 8.5 6.3 6.0 2.1 7.0 3.6 (-) Currency effect 1.1 -2.4 1.0 -3.3 1.0 -3.0 (-) Acquired growth 5.5 – 1.4 1.5 2.9 1.0 Organic growth 1.9 8.7 3.6 3.9 3.1 5.6 Labtech Medtech The Group¹ Q3 Q3 Q3 Q3 Q3 Q3 SEKm 2026 2025 2026 2025 2026 2025 Total growth 77 54 93 30 170 85 (-) Currency effect 10 -20 17 -50 24 -69 (-) Acquired growth 50 – 21 22 71 22 Organic growth 17 74 55 58 75 132 Labtech Medtech The Group¹ Jan-Sep Jan-Sep Jan-Sep Jan-Sep Jan-Sep Jan-Sep % 2026 2025 2026 2025 2026 2025 Total growth 5.0 8.4 2.3 0.3 3.3 3.2 (-) Currency effect -0.7 -2.5 -1.4 -2.6 -1.2 -2.5 (-) Acquired growth 3.5 1.9 1.7 1.0 2.4 1.3 Organic growth 2.2 9.0 2.0 1.9 2.1 4.4 Labtech Medtech The Group¹ Jan-Sep Jan-Sep Jan-Sep Jan-Sep Jan-Sep Jan-Sep SEKm 2026 2025 2026 2025 2026 2025 Total growth 145 224 112 15 256 241 (-) Currency effect -20 -65 -68 -122 -89 -186 (-) Acquired growth 102 51 83 47 185 98 Organic growth 63 238 97 90 160 329 ¹The Group includes eliminations Profit growth EBITA / Profit growth adjusted EBITA Sep 30 Sep 30 Full year SEKm 2026 2025 2025 EBITA (rolling 12 months) 1,501 1,266 1,417 (-) Previous year's EBITA (rolling 12 months) 1,266 1,091 1,159 EBITA growth 235 175 258 Profit growth EBITA, % 19 16 22 Adjusted EBITA (rolling 12 months) 1,311 1,266 1,259 (-) Previous year's adjusted EBITA (rolling 12 months) 1,266 1,077 1,165 Adjusted EBITA growth 45 189 94 Profit growth adjusted EBITA, % 4 18 8 AddLife | Interim report Q3 2026 28
Page 29
Financial net liabilities and Net debt/equity ratio Sep 30 Sep 30 Full year SEKm 2026 2025 2025 Borrowing 4,343 4,407 4,146 Cash and cash equivalents -477 -286 -813 Financial net debt 3,866 4,121 3,333 Pension liability 57 61 58 Lease liability 571 503 504 Contingent considerations 225 106 124 Provisions 27 30 29 Net interest-bearing debt 4,746 4,821 4,048 Total equity 5,958 5,308 5,447 Net debt/equity ratio, multiple 0.8 0.9 0.7 Financial net liabilities/EBlTDA Sep 30 Sep 30 Full year SEKm 2026 2025 2025 Net interest-bearing debt 4,746 4,821 4,048 EBITDA (rolling 12 months) 1,893 1,644 1,802 Financial net liabilities/EBITDA, multiple 2.5 2.9 2.2 Equity ratio Sep 30 Sep 30 Full year SEKm 2026 2025 2025 Total equity 5,958 5,308 5,447 Total assets 13,625 12,660 12,711 Equity ratio, % 44 42 43 AddLife | Interim report Q3 2026 29
Page 30
Incentive programmes based on call options Outstanding programmes Number of warrants Corresponding number of shares Percentage of total number of shares, % Exercise price Exercise period 2023/2027 205,800 205,800 0.2 155.99 Jun 1, 2026 – Feb 26, 2027 Total 205,800 205,800 Incentive programme based on performance shares Outstanding programmes Number of investment shares Corresponding maximum number of performance shares Percentage of total number of shares, % Vesting period Measurement period LTIP 2026 18,923 88,192 0.1 Aug 31, 2026 – Aug 31, 2029 Jan 1, 2026 – Dec 31, 2028 LTIP 2025 13,064 61,806 0.1 Aug 31, 2025 – Aug 31, 2028 Jan 1, 2025 – Dec 31, 2027 LTIP 2024 22,565 107,760 0.1 Aug 31, 2024 – Aug 31, 2027 Jan 1, 2024 – Dec 31, 2026 Total 54,552 257,758 Shareholders Share in % Shareholders 2026-09-30 Class A-shares Class B-shares of capital of votes RoosGruppen AB 2,256,408 3,838,841 4.98 16.14 Tom Hedelius 2,066,572 – 1.69 12.63 AMF Fonder – 11,730,603 9.58 7.17 SEB Fonder – 9,704,361 7.93 5.93 Cliens Fonder – 7,012,932 5.73 4.29 Odin Fonder – 6,600,008 5.39 4.03 Fjärde AP-fonden – 5,440,000 4.44 3.33 Fidelity Mutual Funds – 5,359,566 4.38 3.28 Swedbank Robur Fonder – 5,309,956 4.34 3.25 Vanguard Funds – 4,727,562 3.86 2.89 Total the 10 biggest shareholders 4,322,980 59,723,829 52.32 62.94 Other shareholders 249,816 57,567,436 47.20 36.70 Total outstanding shares 4,572,796 117,291,265 99.52 99.64 Repurchased own shares Class B – 586,189 0.48 0.36 Total registered shares 4,572,796 117,877,454 100.00 100.00 Source: Euroclear For further information about the share, see AddLife's website: add.life/en/investors/the-share The share The share capital at the end of the interim period amounted to SEK 62 million (62). The number of repurchased own shares amounts to 586,189 Class B, corresponding to 0.48 percent of the total number of shares and 0.36 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 100.56 per share. The average number of treasury shares held during the interim period was 586,189 (586,189). The share price at September 30, 2026, was SEK 172.00. AddLife has an outstanding incentive programme based on call options, corresponding to a total of 205,800 B shares. Issued call options on repurchased shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.0 percent (0.0). During the interim period, the 2022/2026 programme expired without impact, as the exercise price during the exercise period exceeded the share price. AddLife has three outstanding incentive programmes based on performance shares corresponding to a maximum of 257,758 of the Company's Class B shares, which represents approximately 0.2 percent of the total number of shares. Participants receive performance shares provided that employment continues, the investment shares are retained, and the performance conditions are met. These are based on the average annual profit growth (EBITA) during the respective measurement period, as well as sustainability- related goals. During the interim period, SEK 5 million (2) has been expensed as a result of the program. On September 30, 2026, the number of shareholders amounted to 10,477, of which 67.9 percent are Swedish owners with respect to capital share. The 10 largest shareholders controlled 52.32 percent of the capital and 62.94 percent of votes. AddLife | Interim report Q3 2026 30
Page 31
Video conference Investors, analysts and the media are invited to a video conference where President and CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online. The video conference will be held at 9:00 a.m. CEST on October 21, 2026. If you wish to participate via video conference, please follow this link>> The presentation is also available on AddLife YouTube >> Financial calendar Year-end report for January 1 – December 31, 2026, will be published on February 3, 2027 The interim report for January 1 – March 31, 2027, will be published on April 29, 2027 The Annual General Meeting (AGM) of AddLife AB (publ) will be held on May 4, 2027, at 4:00 p.m. CEST, Stockholm The interim report for January 1 – June 30, 2027, will be published on July 16, 2027 The interim report for January 1 – September 30, 2027, will be published on October 22, 2027 For further information, please contact: Fredrik Dalborg, President and CEO, +46 70 516 09 01 Christina Rubenhag, CFO, +46 70 546 72 22 AddLife's interim report is published in Swedish and in an English translation. The Swedish version takes precedence in the event of any discrepancies between the two versions. VISION To improve people’s lives by being a leading and value- creating partner in Life Science. BUSINESS IDEA AddLife adds value for its customers operating in the healthcare sector, from research to care. This is done by offering high-quality, cost-effective service and product solutions to both the private and public sectors in Europe. CORE VALUES Simplicity – Responsibility – Commitment – Innovation. The Group’s core values guide AddLife’s entrepreneurial business model. ADDLIFE IN BRIEF AddLife is an independent partner in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors in Europe. AddLife has 2,300 employees in about 85 operating subsidiaries. The Group currently has net sales of more than SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm. This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CEST on October 21, 2026. AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life, corporate identity number 556995-8126 AddLife | Interim report Q3 2026 31